



May 30, 2019

✓ **BSE Limited,**
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards India Packaging Award 2019 won by the Company for its patient awareness initiative 'Lupin Sahayak' and its special packaging for Telista. The India Packaging Award 2019 given by UBM India was received for the category 'Innovation in Patient Awareness Award'.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**

R. V. Satam
For **R. V. SATAM**
COMPANY SECRETARY



Encl.: a.a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

Lupin wins Packaging Award for its patient awareness initiative 'Lupin Sahayak'

Mumbai, May 30, 2019: Pharma major Lupin Limited (Lupin) announced today that it has won the **India Packaging Award 2019** for its patient awareness initiative 'Lupin Sahayak' and its special packaging for Telista. Telista is Lupin's brand of Telmisartan and combinations that is used in the treatment of hypertension (high blood pressure), prevention of heart attack and stroke. Lupin Sahayak is a new initiative by Lupin's Synox Team, that focuses on diabetes and hypertension. It offers a 24x7 WhatsApp helpline (7777044111) that will enable patients to get more information on hypertension.

The India Packaging Award 2019 given by UBM India was received for the category '**Innovation in Patient Awareness Award**'.

Speaking on the win **Mr. Rajeev Sibal, President – India Region Formulations, Lupin Limited** said, *"Packaging is a key focus area for us and it is critical to get this right in keeping with the needs of customers. We at Lupin are delighted with this recognition on innovative packaging that enables patient awareness and meets the need of our valued customers."*

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Dec 2018, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Dec 2018, Bloomberg LTM); 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).

For the financial year ended 31st March 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

Press Note



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66408237

Safe Harbor Statement